AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10424986 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose and Single Bond adhesives
Number of subjects: 48
Study 10424986 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step and Optibond FL adhesives
Number of subjects: 48
Study 7478701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0-40 mg, i.m., 8 times per day)
Number of subjects: 1
Study 1519493 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUD
Number of subjects: 200
Study 1519493 — intervention group
Group type: COMPARATOR
Intervention: Norplant-2
Number of subjects: 200
Study 1519493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 200
Study 6676926 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam/glucagon
Number of subjects: 0
Study 6676926 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam/atropine
Number of subjects: 0
Study 6676926 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine/glucagon
Number of subjects: 0
Study 6676926 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine/atropine
Number of subjects: 0
Study 6676926 — intervention group
Group type: COMPARATOR
Intervention: pethidine
Number of subjects: 0
Study 6676926 — intervention group
Group type: COMPARATOR
Intervention: glucagon
Number of subjects: 0
Study 6676926 — intervention group
Group type: COMPARATOR
Intervention: atropine
Number of subjects: 0
Study 29549496 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 docosapentaenoic acid (ObA)
Number of subjects: 0
Study 29549496 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA, EPA, Omega-3 Index (O3I)
Number of subjects: 0
Study 30234999 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) applied at tendon-to-bone interface
Number of subjects: 54
Study 30234999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 54
Study 24793536 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI (fluticasone furoate/vilanterol), 100/25 µg
Number of subjects: 26
Study 24793536 — intervention group
Group type: COMPARATOR
Intervention: FF (fluticasone furoate), 100 µg
Number of subjects: 26
Study 22540141 — intervention group
Group type: EXPERIMENTAL
Intervention: High-output VNS (1.75mA)
Number of subjects: 41
Study 22540141 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-output VNS (0.25mA)
Number of subjects: 41
Study 22540141 — intervention group
Group type: EXPERIMENTAL
Intervention: High-output VNS (1.75mA) after initial phases
Number of subjects: 41
Study 22540141 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall seizure severity
Number of subjects: 41
Study 19953771 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-bleaching (illumine Home, 10% carbamide peroxide, trays, overnight, for two weeks)
Number of subjects: 75
Study 19953771 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching (Illumine Office, 15% hydrogen peroxide, trays for 45 minutes, three times over three weeks)
Number of subjects: 75
Study 19953771 — intervention group
Group type: COMPARATOR
Intervention: Whitestrips (strips, twice a day, 30 minutes each for two weeks)
Number of subjects: 75
Study 17300629 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG revaccination at 19 months
Number of subjects: 1433
Study 17300629 — intervention group
Group type: COMPARATOR
Intervention: Control group (no revaccination)
Number of subjects: 1433
Study 15673497 — intervention group
Group type: EXPERIMENTAL
Intervention: Design Fluency
Number of subjects: 0
Study 15673497 — intervention group
Group type: EXPERIMENTAL
Intervention: Word Fluency
Number of subjects: 0
Study 15673497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinker Toy Test
Number of subjects: 0
Study 15673497 — intervention group
Group type: EXPERIMENTAL
Intervention: Story Telling Tests
Number of subjects: 0
Study 11148556 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet intervention with telephone counseling
Number of subjects: 1010
Study 11148556 — intervention group
Group type: COMPARATOR
Intervention: General dietary guidelines to reduce disease risk (comparison group)
Number of subjects: 1010
Study 11148556 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (total group)
Number of subjects: 1010
Study 11148556 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with baseline BMI > or = 25 kg/m2
Number of subjects: 1010
Study 11148556 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 1010
Study 9778302 — intervention group
Group type: EXPERIMENTAL
Intervention: Blom-Singer prosthesis
Number of subjects: 52
Study 9778302 — intervention group
Group type: COMPARATOR
Intervention: Provox prosthesis
Number of subjects: 52
Study 7937384 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 0
Study 7937384 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive epidural anesthesia
Number of subjects: 0
Study 7937384 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 0
Study 3281764 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.35 mg.kg‐1 bolus followed by 0.07 mg.kg‐1.hr‐1 infusion for 24 hr)
Number of subjects: 100
Study 3281764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31963808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum Q180 (LPQ180) for 12 weeks
Number of subjects: 70
Study 30305252 — intervention group
Group type: EXPERIMENTAL
Intervention: Numbers + graphic representation + conceptual illustrations
Number of subjects: 0
Study 30305252 — intervention group
Group type: COMPARATOR
Intervention: Numbers only
Number of subjects: 0
Study 30305252 — intervention group
Group type: EXPERIMENTAL
Intervention: Numbers + graphic representation
Number of subjects: 0
Study 30305252 — intervention group
Group type: EXPERIMENTAL
Intervention: Numbers + conceptual illustrations
Number of subjects: 0
Study 27765312 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 5845
Study 27765312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5845
Study 25076278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ylang ylang essential oil by cutaneous application
Number of subjects: 34
Study 25076278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ylang ylang essential oil by inhalation
Number of subjects: 34
Study 25076278 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ylang ylang essence through cutaneous application)
Number of subjects: 34
Study 23332981 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 629
Study 23332981 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced injection frequency
Number of subjects: 629
Study 23332981 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent decreased drug injection and increased alcohol consumption
Number of subjects: 629
Study 20156209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 236
Study 20156209 — intervention group
Group type: COMPARATOR
Intervention: LNG-IUS
Number of subjects: 236
Study 19450093 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage medical exercise therapy (HD)
Number of subjects: 61
Study 19450093 — intervention group
Group type: COMPARATOR
Intervention: Low-dosage medical exercise therapy (LD)
Number of subjects: 61
Study 16686385 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 2% lidocaine and adrenaline 1:200,000 (group I)
Number of subjects: 108
Study 16686385 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL of 1% lidocaine and adrenaline 1:400,000 (group II)
Number of subjects: 108
Study 16686385 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL of 1% lidocaine and adrenaline 1:200,000 (group III)
Number of subjects: 108
Study 16686385 — intervention group
Group type: COMPARATOR
Intervention: 4 mL of 1% lidocaine (group IV)
Number of subjects: 108
Study 12839378 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy: lansoprazole 30 mg twice daily, amoxycillin 500 mg four times daily, clarithromycin 500 mg twice a day for 10 days
Number of subjects: 68
Study 12839378 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy: tri-potassium dicitrato bismuthate 120 mg four times daily, metronidazole 400 mg thrice daily, tetracycline 500 mg four times daily for 10 days
Number of subjects: 68
Study 10791133 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol plus prednisolone
Number of subjects: 51
Study 10791133 — intervention group
Group type: COMPARATOR
Intervention: Albuterol plus placebo
Number of subjects: 51
Study 9025129 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CPR
Number of subjects: 12
Study 9025129 — intervention group
Group type: COMPARATOR
Intervention: Active compression-decompression CPR
Number of subjects: 12
Study 1477847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG) with Sodium Valproate (VPA)
Number of subjects: 16
Study 1477847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG) without Sodium Valproate (VPA)
Number of subjects: 16
Study 1477847 — intervention group
Group type: COMPARATOR
Intervention: Sodium Valproate (VPA)
Number of subjects: 16
Study 1477847 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin (GVG)
Number of subjects: 16
Study 6742088 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical tonic neck reflex (ATNR) in adults with hemiplegia
Number of subjects: 14
Study 6742088 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of rotation used to elicit the reflex
Number of subjects: 14
Study 30625204 — intervention group
Group type: EXPERIMENTAL
Intervention: More cognitively demanding task
Number of subjects: 105
Study 30625204 — intervention group
Group type: COMPARATOR
Intervention: Less cognitively demanding task
Number of subjects: 105
Study 30625204 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive to restrain drinking
Number of subjects: 105
Study 30625204 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit measures of alcohol-related associations
Number of subjects: 105
Study 29668448 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of tranexamic acid per kg (group A)
Number of subjects: 90
Study 29668448 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 90
Study 29668448 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 90
Study 29668448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 27333010 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix Graft (ADMG) and Enamel Matrix Derivative (EMD)
Number of subjects: 19
Study 27333010 — intervention group
Group type: COMPARATOR
Intervention: Acellular Dermal Matrix Graft (ADMG) alone
Number of subjects: 19
Study 24726066 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based occupational therapy for 10 weeks according to national practice guidelines
Number of subjects: 191
Study 24726066 — intervention group
Group type: COMPARATOR
Intervention: Usual care with no occupational therapy
Number of subjects: 191
Study 23610854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% with sufentanil 0.5 microg/ml (group 1)
Number of subjects: 63
Study 23610854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125% with sufentanil 0.5 microg/ml (group 2)
Number of subjects: 63
Study 23610854 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125% with sufentanil 0.5 microg/ml (group 3)
Number of subjects: 63
Study 20491746 — intervention group
Group type: EXPERIMENTAL
Intervention: PN 400 containing 30 mg esomeprazole
Number of subjects: 28
Study 20491746 — intervention group
Group type: EXPERIMENTAL
Intervention: PN 400 containing 20 mg esomeprazole
Number of subjects: 28
Study 20491746 — intervention group
Group type: EXPERIMENTAL
Intervention: PN 400 containing 10 mg esomeprazole
Number of subjects: 28
Study 20491746 — intervention group
Group type: COMPARATOR
Intervention: Naproxen plus esomeprazole 20 mg
Number of subjects: 28
Study 17564755 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg retarded release levodopa/carbidopa
Number of subjects: 13
Study 17564755 — intervention group
Group type: COMPARATOR
Intervention: 150 mg levodopa/carbidopa/entacapone
Number of subjects: 13
Study 16218781 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus‐delivered fibroblast growth factor‐4 (Ad5FGF‐4)
Number of subjects: 13
Study 16218781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 12049555 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10607255 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 125 mg (n = 15)
Number of subjects: 20
Study 10607255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 20
Study 10607255 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 125 mg
Number of subjects: 20
Study 7829789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 1 mg twice daily
Number of subjects: 1436
Study 7829789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg twice daily
Number of subjects: 1436
Study 7829789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg twice daily
Number of subjects: 1436
Study 7829789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1436
Study 2162186 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation of retroperitoneal lymph nodes
Number of subjects: 156
Study 2162186 — intervention group
Group type: COMPARATOR
Intervention: Surveillance only
Number of subjects: 156
Study 2162186 — intervention group
Group type: COMPARATOR
Intervention: Observation group with pure embryonal carcinomas
Number of subjects: 156
Study 2162186 — intervention group
Group type: COMPARATOR
Intervention: Observation group with vascular involvement
Number of subjects: 156
Study 79764 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent pseudomonas vaccine
Number of subjects: 38
Study 79764 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 38
Study 30538070 — intervention group
Group type: EXPERIMENTAL
Intervention: IN Ketamine (1 ml = 50 mg)
Number of subjects: 100
Study 30538070 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline, 1 ml)
Number of subjects: 100
Study 27491438 — intervention group
Group type: EXPERIMENTAL
Intervention: Small aortic root
Number of subjects: 1560
Study 25577501 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention program (6 sessions for children, 2 sessions for parents)
Number of subjects: 30
Study 25577501 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention program
Number of subjects: 30
Study 22926087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue assessment using the subscale of the Checklist Individual Strength, assessed monthly between T2 and T3.
Number of subjects: 60
Study 22926087 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative interactions, impaired sleep and rest, fatigue catastrophizing, and lower self-reported physical activity at T2.
Number of subjects: 60
Study 22926087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for postcancer fatigue, aimed at the fatigue-perpetuating factors, could be offered from two months after successful cancer treatment.
Number of subjects: 60
Study 21977863 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (n = 40)
Number of subjects: 80
Study 21977863 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (n = 40)
Number of subjects: 80
Study 19700194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg at baseline and months 1, 3, and 5)
Number of subjects: 126
Study 19700194 — intervention group
Group type: COMPARATOR
Intervention: Focal/grid laser photocoagulation (at baseline and month 3 if needed)
Number of subjects: 126
Study 19700194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ranibizumab (0.5 mg) and focal/grid laser (at baseline and month 3)
Number of subjects: 126
Study 19700194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 126
Study 19700194 — intervention group
Group type: COMPARATOR
Intervention: Focal/grid laser photocoagulation
Number of subjects: 126
Study 19700194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ranibizumab and focal/grid laser
Number of subjects: 126
Study 19700194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 126
Study 19700194 — intervention group
Group type: COMPARATOR
Intervention: Focal/grid laser
Number of subjects: 126
Study 16436842 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 176
Study 16436842 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 176
Study 15596352 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickened infant formula with lactase activity
Number of subjects: 109
Study 15596352 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 109
Study 11122217 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 subjects, study group)
Number of subjects: 30
Study 11122217 — intervention group
Group type: COMPARATOR
Intervention: BDP (10 subjects, control group)
Number of subjects: 30
Study 9404431 — intervention group
Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure of 80 mmHg
Number of subjects: 18790
Study 9404431 — intervention group
Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure of 85 mmHg
Number of subjects: 18790
Study 9404431 — intervention group
Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure of 90 mmHg
Number of subjects: 18790
Study 9404431 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatments
Number of subjects: 18790
Study 9404431 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy in the 80 mmHg target group
Number of subjects: 18790
Study 9404431 — intervention group
Group type: COMPARATOR
Intervention: Bitherapy in the 85 mmHg target group (France)
Number of subjects: 18790
Study 8453217 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective red cell transfusion to maintain capillary haematocrit greater than 0.35 l/1 (group 1)
Number of subjects: 19
Study 8453217 — intervention group
Group type: COMPARATOR
Intervention: No transfusion (group 2)
Number of subjects: 19
Study 8453217 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 19
Study 3705896 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (4 mg) mixed with 10 ml of orange juice
Number of subjects: 40
Study 3705896 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline mixed with 10 ml of orange juice
Number of subjects: 40
Study 30336337 — intervention group
Group type: EXPERIMENTAL
Intervention: High poverty neighborhoods
Number of subjects: 632
Study 30336337 — intervention group
Group type: COMPARATOR
Intervention: Low poverty neighborhoods
Number of subjects: 632
Study 29019855 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC)
Number of subjects: 40
Study 29019855 — intervention group
Group type: COMPARATOR
Intervention: Donor milk (DM) / Infant formula (IF)
Number of subjects: 40
Study 27055283 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia Rapid Screening Tool (FiRST)
Number of subjects: 770
Study 27055283 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with total FiRST score
Number of subjects: 770
Study 24667753 — intervention group
Group type: EXPERIMENTAL
Intervention: Interesterified palm olein (IPO)
Number of subjects: 50
Study 24667753 — intervention group
Group type: EXPERIMENTAL
Intervention: Lard
Number of subjects: 50
Study 24667753 — intervention group
Group type: COMPARATOR
Intervention: High oleic sunflower (HOS) oil
Number of subjects: 50
Study 24667753 — intervention group
Group type: COMPARATOR
Intervention: Palm olein (PO)
Number of subjects: 50
Study 22466383 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (100 two-footed jumps with a rope and standardized muscle strength exercise) for 12 weeks
Number of subjects: 54
Study 22466383 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 54
Study 20619212 — intervention group
Group type: EXPERIMENTAL
Intervention: Video and booklet intervention
Number of subjects: 158
Study 20619212 — intervention group
Group type: EXPERIMENTAL
Intervention: Any part of the intervention (video or booklet)
Number of subjects: 158
Study 19194534 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2201
Study 19194534 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 2201
Study 19194534 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI (highest tertile risk)
Number of subjects: 2201
Study 19194534 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone (highest tertile risk)
Number of subjects: 2201
Study 19194534 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 2201
Study 16084851 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (N = 30)
Number of subjects: 40
Study 16084851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (N = 10)
Number of subjects: 40
Study 11929046 — intervention group
Group type: EXPERIMENTAL
Intervention: Porphyria cutanea tarda patients
Number of subjects: 111
Study 11929046 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 111
Study 10430114 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated titration regimen of sotalol (80 mg every 6 hours for four doses, then 160 mg every 12 hours for nine doses)
Number of subjects: 34
Study 10430114 — intervention group
Group type: COMPARATOR
Intervention: Standard titration regimen of sotalol (80 mg every 6 hours for eight doses, then 160 mg every 12 hours for nine doses)
Number of subjects: 34
Study 7756495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1-g intravenous dose)
Number of subjects: 511
Study 7756495 — intervention group
Group type: COMPARATOR
Intervention: Cefotetan (1-g intravenous dose)
Number of subjects: 511
Study 2405040 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (approximately 28 mg) administered by inhalation
Number of subjects: 10
Study 2405040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10